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Lung cancer is the leading cause of cancer-related death worldwide. Recent advances in the management of non-
small cell carcinoma are focused on the discovery of targeted therapies and novel immunotherapy strategies for
patients with advanced disease. Treatment with anti PD-(L)1 immune checkpoint inhibitors requires the devel-
opment of predictive biomarkers to select those patients that can most benefit from these therapies. Several
immunohistochemical biomarkers have been developed in different technological platforms. However, the most
useful and accessible for the daily clinical practice need to be selected. The objective of this study was to compare
PD-L1 expression by automated immunohistochemistry in lung adenocarcinoma (ADC) FFPE samples with clones
28-8 and SP263 performed with the BenchMark GX automated staining instrument. To further determine inter-
observer agreement between two pathologists, and to correlate the results with histologic and pathology vari-
ables. FFPE tissue from 40 samples obtained from patients with lung ADC were reviewed retrospectively. Among
all studied specimens, 53% of samples presented <1% of positive tumor cells with the 28-8 clone and 50% had
<1% of PD-L1 expression in tumor cells with the SP263 clone; PD-L1 expression between 1 and <5% was
observed in 18% and 24%; 5 and <50% PD-L1 expression in 18% and 21%; and 50% PD-L1 expression in 11%
and 5% of samples, respectively. Similar results between antibodies were observed in 84% of cases for each of the
four PD-L1 cutoff groups (Pearson's score 0.90, p < 0.00001). The interobserver degree of agreement calculated
with Kappa was 0.75 (95%CI: 0.57–0.93), z ¼ 7.08; p < 0.001. Lepidic, acinar and mucinous patterns had pre-
dominantly <1% PD-L1 expression, and the solid pattern subtype had high levels of PD-L1 staining using both
clones. PD-L1 expression in less than 1% of tumor cells was similar in stages I/II compared to III/IV. No significant
differences were observed in PD-L1 staining and quantification pattern between IHC antibodies 28-8 and SP263.1. Introduction
Lung cancer is the leading cause of cancer-related death worldwide
[1]. In Argentina, 10,296 new cases are diagnosed and 9,254 people die
every year [2]. Non-small cell lung carcinomas (NSCLC) are divided in 3
main categories: adenocarcinoma (ADC), squamous cell carcinoma (SCC)
and large cell carcinoma [3]. NSCLC is characterized by the presence of
genetically distinct and dynamic subpopulations within the same tumor,
which can have an impact on treatment outcomes. To select patients for
targeted therapies like kinase inhibitors, we need test for driver alter-
ations involving EGFR, ALK, ROS1, and BRAF as standard practice for
patients with advanced tumors [4, 5, 6, 7]. The discovery ofr (V. Denninghoff).
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has enabled novel treatments in a wide range of tumor types. Immune
surveillance is essential to prevent the development of cancer and is
associated with the expression of neo-antigens by tumor cells as result of
somatic mutations in genes, viral antigen presentation [7, 8, 9].
The use of immunohistochemical analysis for the determination of
PD-L1 has been proposed as a prognostic and predictive biomarker for
anti-PD-1 and anti-PD-L1 monoclonal antibodies in the clinical scenario
of advanced NSCLC. The Food and Drug Administration (FDA) requires
the development of diagnostic tests, either as “companion” or compul-
sory for such a drug, or “complementary”, which means recommended
(eg. PD-L1 28-8 antibody [Abcam] using the DAKO detection system).May 2020
he CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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developed as biomarker tests including: 22C3 (Dako’ Platform), 28-8
(pharm Dx, Dako's Platform), SP142 (Spring Bioscience, Ventana's Plat-
form), E1L3N and E1J2J (Cell Signaling Technologies, Ventana's Plat-
form), SP263 (Ventana's Platform), 7G11 (Boston University), EPR1161-
2 (Epitomics-Abcam); etc [10]. Available companion diagnostic tests use
specific assays with different clones, staining protocols, automated
platforms, scoring interpretation and target cells (tumor and/or immune
cells). In addition, different PD-L1 cutoffs are being selected for anti
PD-(L)1 treatment in the first or second line therapy, and PD-L1
expression is a dynamic marker subject to temporospatial heterogeneity.
Given the diversity of testing platforms, worldwide efforts are made
to “harmonize” PD-L1 testing to facilitate clinical decision-making. Thus,
the National Cancer Institute in France developed a national validation
study with different antibodies and platforms searching for technical
equivalences [11]; the International Pulmonary Pathology Society [12];
the Colonia Score in Germany [13]; the Blueprint PD-L1 Assay Com-
parison Project [14, 15] and the Harmonization study in Israel [16].
The objective of this study was to compare PD-L1 expression by
automated immunohistochemistry in lung adenocarcinoma (ADC) FFPE
samples in our country with anti PD-L1 clones 28-8 and SP263 performed
with the BenchMark GX automated staining platform. Interobserver
agreement between two observers was analyzed and results were
correlated with pathological data.
2. Materials and methods
We retrospectively studied forty non-matched biopsies from patients
with lung ADC, fixed in 10% buffered formalin, paraffin embedded, and
then cut into sections of 4 μm. These samples underwent immunohisto-
chemistry testing using PD-L1 rabbit monoclonal antibody, clones 28-8
(Abcam, Cambridge, UK) and SP263 (Ventana Medical Systems Inc,
Tucson, USA). Immunohistochemical staining was performed with
BenchMark GX immunoautomate (Ventana Medical Systems Inc, Tucson,
USA), OptiView DAB IHC Detection Kit and OptiView Amplification Kit
(Ventana Medical Systems Inc, Tucson, USA). Staining was evaluated by
two pathologists with expertise in thoracic pathology, IHC and PD-L1
assessment. Both pathologists blinded to clinical data scored the pro-
portion of PD-L1 in tumor cells for each biopsy independently. For tumor
cells, the proportion of PD-L1 positive cells was estimated as the per-
centage of PD-L1 positive tumor cells over the total tumor cells. Although
ADC is a heterogeneous tumor type and several histological patterns may
coexist in the same sample, PD-L1 staining was evaluated in the whole
slide, irrespective of cell type. Interobserver agreement between two
observers was evaluated using the Kappa test in each of the four groups
where the results were divided based on cutoffs from recently published
studies (<1%, 1 to <5%, 5 to <50% and 50%) [17, 18]. Alpha
significance level was p ¼ 0.05. No binary limit was applied.
The study protocol was approved by the Institutional Ethics Com-
mittee. This study was performed in compliance with the good clinical
practice (GCP), as defined by the International Conference on Harmo-
nization (ICH). This protocol fully complies with the International
Declaration on human genetic data, approved unanimously and byTable 1. PD-L1 results and histological patterns with clones 28.8 and SP263.
% of positive tumor cells clone 28.8
cases Histological pattern
<1 53% acinar/lepidic 66%mucinous 17%
1 to <5 18% acinar/lepidic 100%
5 to <50 18% beside other patterns,solid pattern
50 11% acinar 50%solid pattern 50%
Cut-off 5 %, PD-L1 þ: 29%
Cut-off 1 %, PD-L1 þ: 47%
2
acclamation, by the UNESCO General Conference 32nd session, October
16, 2003. All data obtained were handled with absolute confidentiality
according to national legislation (Ley de proteccion de Datos Personales,
Habeas Data), and could only be accessed by the researchers involved in
the study or the members of the institutional Ethics Committee.
3. Results
A total of 40 patients were included, 18 males and 22 females, with a
mean age of 65 years (range: 31–84). Twenty-three were surgically
resected specimens and 17 were biopsy specimens (endoscopic, core and
fine needle aspiration). Cancer stage at diagnosis was: Ia 17%, Ib 25%, IIa
8%, IIIb 3%, and IV 47%.
Regarding PD-L1 staining, 53% were classified as having <1% of PD-
L1 positive tumor cells using the 28-8 clone, and 50% of the samples had
<1% of PD-L1 positive tumor cells with the SP263 clone. Using the 28-8
clone, 18% of samples were classified as having 1% to <5% PD-L1
positive tumor cells and 24% of samples were classified in this cutoff
using SP263 antibody. Similarly, 18% of samples were scored as having
5% to <50% PD-L1 positive tumor cells using the 28-8 clone, and 21%
using the SP263 clone. In addition, 11% and 5% of samples had a 50%
PD-L1 expression in tumor cells using the 28-8 and SP263 clones,
respectively. Matching results were observed in 84% of cases in all four
categories, showing a high level of correlation between assays (Pearson's
score 0.90, p < 0.00001).
Overall, 47% of lung ADC samples were PD-L1 positive (1%) with
28–8 antibody, and 50%with SP263 antibody. Using a cutoff of>5% PD-
L1 positive tumor cells, 29% were positive using the 28-8 antibody and
26% of samples using SP263 antibody. The association between PDL1
and histological pattern is shown in Tables 1 and 2. Lepidic, acinar and
mucinous patterns predominantly showed low PD-L1 expression (PD-L1
TPS <1%); however, the solid pattern had high levels of PD-L1 staining
with both clones. Table 3 showed the relationship between PD-L1 results
and clinical stage. Interobserver degree of agreement calculated with
Kappa was 0.75 (95%CI: 0.57–0.93), z ¼ 7.08; p < 0.001.
4. Discussion
The prescription of different anti PD-(L)1 drugs for the same disease
depends on IHC PD-L1 testing with a specific antibody and platform.
Pathologists have to face the challenge of working with different anti-
body clones, staining protocols, platforms, scoring systems and cutoffs
[19]. Other issues with an impact on PD-L1 assessment include: tumor
heterogeneity, dynamic nature of PD-L1 expression, which varies be-
tween anatomical sites, time of biopsy, type of treatments, epitopes with
high sensitivity to fixation and composition of tumor microenvironment
[20, 21].
In the initial findings from the Blueprint Programmed Death Ligand 1
Immunohistochemistry Assay Comparison Project, three experts, inde-
pendently, evaluated the percentages of tumor and immune cells staining
positive in 39 NSCLCs using 22C3, 28-8, SP142 and SP263. This com-
parison revealed a similar percentage of stained tumor cells between
22C3, 28-8 and SP263 assays, whereas the SP142 assay exhibited overallclone SP263
cases Histological pattern
solid 17% 50% acinar/lepidic 64%mucinous 22%solid 14%
24% acinar/lepidic 88%solid 12%
66% 21% beside other patterns,solid pattern 63%
5% acinar 50%solid pattern 50%
26%
50%
Table 3. PD-L1 percentage and its relationship with clinical stage.
% of positive tumor cells Stage l/ll Stage III/lV
<1 41% 59%
1 to <5 86% 14%
5 to <50 83% 17%
50 25% 75%
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50 acinar: 100% solid: 100%
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corroborated these findings with a larger number of cases and observers.
However, most specimens were obtained surgically, rather than by
percutaneous biopsies, which are the most frequent type of diagnostic
specimens in advanced NSCLC [15]. A collaborative study performed in
Israel by Neuman et al. assessed the harmonization for the use of 22C3
clone on Ventana's platform. Neither in Argentina, nor in Israel is the
Dako platform and/or the In Vitro Diagnostic (IVD) kit easily available.
Therefore, Neuman et al. performed a comprehensive staining calibration
on the BenchMark XT platform using Dako's prediluted 22C3 anti-PD-L1
primary antibody with two Ventana detection systems: Forty one 41
NSCLC cases independently evaluated by two pathologists proving that
same PD-L1 IHC algorithm can be reliably applied to Ventana's Bench-
Mark XT platform, and that all of the strongly positive cases had high
interobserver and intraobserver agreement [16].
Adam et al. further showed that laboratory-developed tests (LDTs)
have various levels of agreement when compared with three commercial
assays. Those using SP263 clone had the greatest agreement across all
platforms, whereas some LTDs with 28–8, 22C3, and E1L3N showed
good correlation with the three commercial assays for tumoral cells only
[22]. Assessment of tumor cells (TCs) score in NSCLC was highly
reproducible using the SP263 assay, showing the accuracy of this assay in
patient selection for anti-PD-1/PD-L1 therapy. The overall diagnostic
sensitivity and specificity analyses indicated that the relative analytical
sensitivities of the Food and Drug Administration-approved kits for
tumor cell scoring, most specifically in non-small cell lung cancer, were
as follows: Ventana PD-L1 (SP142) had the lowest sensitivity/specificity,
followed by PD-L1 IHC 22C3 pharmDx, PD-L1 IHC 28-8 pharmDx and
PD-L1 SP263 Ventana assay with the highest score [23].
In our study there was a concordance between the 28-8 and SP246
PD-L1 clones in 84% of the cases (Pearson's score 0.90, p < 0.00001).
However, as Williams et al., we adopted VENTANA PD-L1 (SP263) Assay
in our clinical practice as a reliable and reproducible assay [24]. In our
experience, especially in solid pattern tumors with abundant immune
cells, 28-8 stains both populations too intensely, thus making quantifi-
cation difficult. On the other hand, the SP263 assay stains sections
delicately and allows more reliable identification of tumor cells. Never-
theless, our interobserver degree of agreement calculated with Kappa
was 0.75 (95%CI: 0.57–0.93), z ¼ 7.08; p < 0.001).
Both clones performed adequately PD-L1 expression to the histolog-
ical pattern. Regarding the relationship between PDL1 and histological
pattern, it can be hypothesized that poorly differentiated ADC (solid
pattern) could present a higher tumor mutational burden (TMB) which
could result in enhanced immunogenic tumors. On the other hand, well3
differentiated tumors (lepidic, acinar, etc.) usually have less genetic al-
terations and consequently lower levels of neoantigens presentation.
However, TMB and PD-L1 tumor expression correlate poorly and are
considered independent biomarkers of treatment response [26]. In this
study TMB assessment was not performed on tumor samples.
Comparison of surgical (complete tumors) and biopsy specimens re-
veals that the focal solid pattern seen in surgical specimens fails to be
seen in biopsy specimens. Since half of the cases with <1% stained cells
were small samples (biopsies), these results should be interpreted as a
consequence of the heterogeneous staining phenomenon. Ilie et al. re-
ported on the possible difference in PD-L1 expression when comparing
whole surgical tissue sections and matched lung biopsies using SP142.
They found that PD-L1 expression was frequently discordant between
both types of specimens (overall discordance rate ¼ 48%, 95% confi-
dence interval 4.64–13.24 and Kappa ¼ 0.218) [25]. In all cases, biopsy
specimens underestimated the PD-L1 status observed in the whole tissue
sample. Their findings would indicate a poor association of PD-L1
expression in tumor and immune cells between lung biopsies and cor-
responding resected tumors. Moreover, the daily routine evaluation of
PD-L1 expression in diagnostic biopsies can be misleading in defining the
treatment with PD-(L)1 inhibitors26.
PD-L1 expression <1% had a similar distribution between stages I/II,
compared to stages III/IV. However, the expression 1 to <50 was 85%
for I/II stage, 50% in 75% of stage III/IV cases. These results would
reveal a trend that needs further confirmation with a larger number of
samples.
This is a real-life study in a developing country [22]. Therefore, PD-L1
assay selection is mainly based on both the platform and trained pa-
thologists availability. Approaches to harmonizing testing methods are
therefore crucial in ensuring appropriate treatment selection for our
patients.
Our study has several limitations. Firstly, the number of studied
samples is rather low. However, this is the largest study presented in our
region. Secondly, only two PD-L1 testing platforms were evaluated, and
therefore the results of this study cannot be extrapolated to other PD-L1
antibodies (22C3, SP142). Thirdly, since this study was not performed in
other subtypes of non-small cell lung cancers, these results should not be
extrapolated to squamous-cell carcinomas.
In conclusion, immunostaining with anti PD-L1 clones 28-8 and
SP263 has high levels of correlation, in concordance with other studies.
This correlation is maintained across different histological subtypes and
clinical stage, however PD-L1 staining could be underestimated in small
samples. PD-L1 testing needs to be cost-effective, developed with a ho-
listic approach to be applied in multiple indications to meet patients'
needs. However, it must be interpreted in the context of other tumor and
patient immunologic factors with an impact on the response and prog-
nosis with immunotherapy, such as tumor mutation burden, microsat-
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